105 related articles for article (PubMed ID: 38865146)
1. Worst Itch Numeric Rating Scale for Prurigo Nodularis: A Secondary Analysis of 2 Randomized Clinical Trials.
Kwatra SG; Yosipovitch G; Kim B; Stander S; Rhoten S; Ivanescu C; Haeusler N; Brookes E; Msihid J; Makhija M; Bansal A; Thomas RB; Bahloul D
JAMA Dermatol; 2024 Jun; ():. PubMed ID: 38865146
[TBL] [Abstract][Full Text] [Related]
2. Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Associated With Prurigo Nodularis: A Secondary Analysis of a Randomized Clinical Trial.
Kimel M; Zeidler C; Kwon P; Revicki D; Ständer S
JAMA Dermatol; 2020 Dec; 156(12):1354-1358. PubMed ID: 32936233
[TBL] [Abstract][Full Text] [Related]
3. Worst itch numerical rating scale for prurigo nodularis: a psychometric evaluation.
Ständer S; Zeidler C; Pereira M; Szepietowski JC; McLeod L; Qin S; Williams N; Sciascia T; Augustin M
J Eur Acad Dermatol Venereol; 2022 Apr; 36(4):573-581. PubMed ID: 34908192
[TBL] [Abstract][Full Text] [Related]
4. Psychometric validation and meaningful change thresholds of the Worst Itching Intensity Numerical Rating Scale for assessing itch in patients with chronic kidney disease-associated pruritus.
Vernon MK; Swett LL; Speck RM; Munera C; Spencer RH; Wen W; Menzaghi F
J Patient Rep Outcomes; 2021 Dec; 5(1):134. PubMed ID: 34952964
[TBL] [Abstract][Full Text] [Related]
5. Validation of the Peak Pruritus Numerical Rating Scale as a Patient-Reported Outcome Measure in Prurigo Nodularis.
Kwatra SG; Rodriguez D; Dias-Barbosa C; Budhiarso I; Fofana F; Vernon M; Gabriel S; Piketty C; Puelles J
Dermatol Ther (Heidelb); 2023 Oct; 13(10):2403-2416. PubMed ID: 37615836
[TBL] [Abstract][Full Text] [Related]
6. Responder analysis using clinically meaningful thresholds: Post hoc analyses from randomized dupilumab clinical trials in patients with prurigo nodularis.
Kwatra SG; Yosipovitch G; Ständer S; Guillemin I; Msihid J; Bansal A; Makhija M; Wiggins S; Zahn J; Thomas RB; Bahloul D
J Eur Acad Dermatol Venereol; 2024 May; ():. PubMed ID: 38785405
[TBL] [Abstract][Full Text] [Related]
7. Estimating meaningful change thresholds for Skin Pain-Numeric Rating Scale, Sleep-Numeric Rating Scale and Dermatology Life Quality Index in patients with prurigo nodularis.
Stander S; Kim BS; Guillemin I; Rhoten S; Wratten S; Brookes E; O'Malley JT; Bansal A; Msihid J; Thomas R; Bahloul D
J Eur Acad Dermatol Venereol; 2024 Feb; ():. PubMed ID: 38329222
[TBL] [Abstract][Full Text] [Related]
8. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials.
Yosipovitch G; Mollanazar N; Ständer S; Kwatra SG; Kim BS; Laws E; Mannent LP; Amin N; Akinlade B; Staudinger HW; Patel N; Yancopoulos GD; Weinreich DM; Wang S; Shi G; Bansal A; O'Malley JT
Nat Med; 2023 May; 29(5):1180-1190. PubMed ID: 37142763
[TBL] [Abstract][Full Text] [Related]
9. Validation of a scoring algorithm for the clinician-reported outcome tool 'prurigo activity and severity (PAS)' based on clinical studies of dupilumab in adults with prurigo Nodularis.
Zeidler C; Stander S; Rhoten S; Wratten S; Zhang D; Msihid J; Brookes E; Thomas R; Bahloul D
J Eur Acad Dermatol Venereol; 2024 Apr; ():. PubMed ID: 38563058
[TBL] [Abstract][Full Text] [Related]
10. The Sleep Disturbance Numerical Rating Scale: Content Validity, Psychometric Validation, and Meaningful Within-Patient Change in Prurigo Nodularis.
Ständer S; Fofana F; Dias-Barbosa C; Rodriguez D; Budhiarso I; Jabbar-Lopez ZK; Piketty C; Vernon M; Puelles J
Dermatol Ther (Heidelb); 2023 Jul; 13(7):1587-1602. PubMed ID: 37329468
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study.
Sofen H; Bissonnette R; Yosipovitch G; Silverberg JI; Tyring S; Loo WJ; Zook M; Lee M; Zou L; Jiang GL; Paolini JF
EClinicalMedicine; 2023 Mar; 57():101826. PubMed ID: 36816342
[TBL] [Abstract][Full Text] [Related]
12. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis.
Silverberg JI; DeLozier A; Sun L; Thyssen JP; Kim B; Yosipovitch G; Nunes FP; Gugiu PC; Doll HA; Eichenfield LF
Health Qual Life Outcomes; 2021 Oct; 19(1):247. PubMed ID: 34688290
[TBL] [Abstract][Full Text] [Related]
13. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis.
Yosipovitch G; Reaney M; Mastey V; Eckert L; Abbé A; Nelson L; Clark M; Williams N; Chen Z; Ardeleanu M; Akinlade B; Graham NMH; Pirozzi G; Staudinger H; Plaum S; Radin A; Gadkari A
Br J Dermatol; 2019 Oct; 181(4):761-769. PubMed ID: 30729499
[TBL] [Abstract][Full Text] [Related]
14. Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis.
Kimball AB; Naegeli AN; Edson-Heredia E; Lin CY; Gaich C; Nikaï E; Wyrwich K; Yosipovitch G
Br J Dermatol; 2016 Jul; 175(1):157-62. PubMed ID: 26852717
[TBL] [Abstract][Full Text] [Related]
15. Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response.
Husein-ElAhmed H; Steinhoff M
J Dermatolog Treat; 2022 May; 33(3):1547-1553. PubMed ID: 33200955
[TBL] [Abstract][Full Text] [Related]
16. A population pharmacokinetic-pharmacodynamic model evaluating efficacy of nalbuphine extended-release in patients with prurigo nodularis.
Eudy-Byrne R; Riggs M; Hawi A; Sciascia T; Rohatagi S
Br J Clin Pharmacol; 2023 Jul; 89(7):2088-2101. PubMed ID: 36680419
[TBL] [Abstract][Full Text] [Related]
17. Development, Psychometric Validation and Responder Definition of Worst Itch Scale in Children with Severe Atopic Dermatitis.
Paller AS; Yosipovitch G; Weidinger S; DiBenedetti D; Whalley D; Gadkari A; Guillemin I; Zhang H; Eckert L; Chao J; Bansal A; Chuang CC; Delevry D
Dermatol Ther (Heidelb); 2022 Dec; 12(12):2839-2850. PubMed ID: 36269504
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
Blauvelt A; Teixeira HD; Simpson EL; Costanzo A; De Bruin-Weller M; Barbarot S; Prajapati VH; Lio P; Hu X; Wu T; Liu J; Ladizinski B; Chu AD; Eyerich K
JAMA Dermatol; 2021 Sep; 157(9):1047-1055. PubMed ID: 34347860
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Abrocitinib in Prurigo Nodularis and Chronic Pruritus of Unknown Origin: A Nonrandomized Controlled Trial.
Kwatra SG; Bordeaux ZA; Parthasarathy V; Kollhoff AL; Alajmi A; Pritchard T; Cornman HL; Kambala A; Lee KK; Manjunath J; Ma EZ; Dillen C; Kwatra MM
JAMA Dermatol; 2024 Jun; ():. PubMed ID: 38837144
[TBL] [Abstract][Full Text] [Related]
20. Assessing Itch Severity: Content Validity and Psychometric Properties of a Patient-Reported Pruritus Numeric Rating Scale in Atopic Dermatitis.
Rams A; Baldasaro J; Bunod L; Delbecque L; Strzok S; Meunier J; ElMaraghy H; Sun L; Pierce E
Adv Ther; 2024 Apr; 41(4):1512-1525. PubMed ID: 38363461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]